Diagnostic value of probe-based confocal laser endomicroscopy versus conventional endoscopic biopsies of non-muscle invasive bladder tumors: a pilot study

Beji, Sami; Lam, Gitte Wrist; Østergren, Peter Busch; Toxværd, Anders; Sønksen, Jens; Fode, Mikkel

doi:10.1080/21681805.2020.1841285

Cited by 6 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some authors reported daunting results. Beji et al concluded that the NPV for CLE was not high enough to safely replace conventional pathology for BC [22]. The authors considered their 82% NPV rate unsafe to omit standard histology, since high-grade lesions may potentially evolve into MIBC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fluorescence Confocal Microscopy in Urological Malignancies: Current Applications and Future Perspectives

Ongaro,

Rossin,

Biasatti

et al. 2023

Life

View full text Add to dashboard Cite

Fluorescence confocal microscopy (FCM) represents a novel diagnostic technique able to provide real-time histological images from non-fixed specimens. As a consequence of its recent developments, FCM is gaining growing popularity in urological practice. Nevertheless, evidence is still sparse, and, at the moment, its applications are heterogeneous. We performed a narrative review of the current literature on this topic. Papers were selected from the Pubmed, Embase, and Medline archives. We focused on FCM applications in prostate cancer (PCa), urothelial carcinoma (UC), and renal cell carcinoma (RCC). Articles investigating both office and intraoperative settings were included. The review of the literature showed that FCM displays promising accuracy as compared to conventional histopathology. These results represent significant steps along the path of FCM’s formal validation as an innovative ready-to-use diagnostic support in urological practice. Instant access to a reliable histological evaluation may indeed significantly influence physicians’ decision-making process. In this regard, FCM addresses this still unmet clinical need and introduces intriguing perspectives into future diagnostic pathways. Further studies are required to thoroughly assess the whole potential of this technique.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The results regarding CFM applications in BC detection are reported in Table 1. Beji et al reported a 48% Se, an 82.7% Sp, a 54.75 PPV, and an 82.3% NPV in their cohort [22]. The CLE capability to distinguish normal mucosa, inflammatory changes, or low-grade UC (LGUC) samples from high-grade (HGUC) has been investigated.…”

Section: Bladder Cancermentioning

confidence: 99%

Fluorescence Confocal Microscopy in Urological Malignancies: Current Applications and Future Perspectives

Ongaro,

Rossin,

Biasatti

et al. 2023

Life

View full text Add to dashboard Cite

show abstract

“…A missed diagnosis can also affect the accurate detection and complete resection of tumors, resulting in recurrent or advanced carcinoma [10,12]. The presence of in ammatory diseases can lead to misdiagnosis [13][14][15]. Under WL cystoscopy, it is di cult to distinguish between in ammatory lesions and cancer, as well as benign and malignant lesions, which often leads to misdiagnosis [16].…”

Section: Introductionmentioning

confidence: 99%

A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer

Shang

Peng

et al. 2022

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Bladder cancer is the fth most common malignancy in humans. Cystoscopy under white light imaging is the gold standard for bladder cancer diagnosis, but some tumors are di cult to visualize and can be overlooked, resulting in high recurrence rates. Method:We developed a phage display-derived peptide-based near-infrared imaging probe, PLSWT7-DMI, which binds speci cally to bladder cancer cells and is nontoxic to animals. Here, we report a clinical research of this probe for near-infrared uorescence endoscopic detection of bladder cancer. ResultsThe purity, e cacy, safety, and nontoxicity of PLSWT7-DMI were con rmed prior to its clinical application. Twenty-two patients diagnosed with suspected non-muscle invasive bladder cancer were enrolled in the present study. Following intravesical administration of the probe, the entire mucosa was imaged under white and near-infrared imaging using an in-house developed endoscope that could switch between these two modes. The illuminated lesions under near-infrared light were biopsied and sent for histopathological examination. We observed a 5.1-fold increase in the uorescence intensity in the tumor samples compared to normal tissue, and the probe demonstrated a sensitivity and speci city of 91.2% and 90%, respectively. Common diagnostic challenges, such as small satellite tumors, carcinoma in situ, and benign suspicious mucosa, were visualized and could be distinguished from cancer. Further, no adverse effects were observed in humans. ConclusionThese rst-in-human results indicate that PLSWT7-DMI-based near-infrared uorescence endoscopy is a safe and effective approach for the improved detection of bladder cancer, and may enable thorough resection to prevent recurrence.

show abstract

Section: Introductionmentioning

confidence: 99%

A Fluorescently-labeled Tumor-specific Peptide for Intraoperative Visualization of Non-muscle Invasive Bladder Cancer: A Clinical Study

Shang

Li²,

et al. 2021

Preprint

View full text Add to dashboard Cite

Bladder cancer is the fifth most common malignancy in humans. Cystoscopy under white light imaging is the gold standard for bladder cancer diagnosis, but these tumors are difficult to visualize and can be overlooked, resulting in high recurrence rates. We previously developed a phage display-derived peptide-based near-infrared imaging probe, PLSWT7-DMI, which binds specifically to bladder cancer cells and is nontoxic to animals. Here, we report the first-in-human application of this probe for near-infrared fluorescence endoscopic detection of bladder cancer. The purity, efficacy, safety, and nontoxicity of the probe were confirmed prior to its clinical application. Twenty-two patients diagnosed with suspected non-muscle invasive bladder cancer were enrolled in the present study. Following intravesical administration of the probe, the entire mucosa was imaged under white and near-infrared imaging using an in-house developed endoscope that could switch between these two modes. The illuminated lesions under near-infrared light were biopsied and sent for histopathological examination. We observed a 5.1-fold increase in the fluorescence intensity in the tumor samples compared to normal tissue, and the probe demonstrated a sensitivity and specificity of 91.2% and 90%, respectively. Common diagnostic challenges, such as small satellite tumors, carcinoma in situ , and benign suspicious mucosa, were visualized and could be distinguished from cancer. Further, no adverse effects were observed in humans. These first-in-human results indicate that PLSWT7-DMI-based near-infrared fluorescence endoscopy is a safe and effective approach for the improved detection of bladder cancer, and may enable thorough resection to prevent recurrence.

show abstract

Diagnostic value of probe-based confocal laser endomicroscopy versus conventional endoscopic biopsies of non-muscle invasive bladder tumors: a pilot study

Cited by 6 publications

References 11 publications

Fluorescence Confocal Microscopy in Urological Malignancies: Current Applications and Future Perspectives

Fluorescence Confocal Microscopy in Urological Malignancies: Current Applications and Future Perspectives

A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer

A Fluorescently-labeled Tumor-specific Peptide for Intraoperative Visualization of Non-muscle Invasive Bladder Cancer: A Clinical Study

Contact Info

Product

Resources

About